 The FDA has granted conditional approval for Jaguar Health Incs NASDAQ: JAGX Canalevia-CA1 crofelemer delayed-release tablets for chemotherapy-induced diarrhea CID in dogs. This is the first and only product indicated for treating chemotherapy-induced diarrhea CID in dogs to receive any approval from the FDA. 